Program Code: HEMOREGEN-IMM-003
Division: HEMOREGEN-IMMUNO
Parent Program: HEMOREGEN-721
Former Code: SCF-VIRA-EVCM-0004C
Classification: Cytotoxic Immune Communication Platform
Status: Master Foundational Blueprint v1.0
EXECUTIVE SUMMARY
The NK/CTL Cytotoxic EV Blueprint defines the extracellular vesicle communication systems used by Natural Killer cells and Cytotoxic T Lymphocytes to identify, engage, and eliminate abnormal target cells.
Within PROJECT HEMOREGEN-721, cytotoxic EVs are classified as precision immune-killing vectors responsible for:
- Tumor surveillance
- Viral clearance
- Senescent-cell removal
- Immune-target confirmation
- Cytotoxic synapse reinforcement
- Long-term recurrence suppression
SECTION I — CYTOTOXIC CELL ARCHITECTURE
Effector Cell | Primary Function |
NK Cells | Innate immune surveillance |
CD8 CTLs | Antigen-specific killing |
NKT Cells | Hybrid innate-adaptive cytotoxicity |
Memory CTLs | Long-term recurrence surveillance |
SECTION II — CYTOTOXIC EV CARGO ATLAS
Cargo Class | Representative Cargo | Function |
Direct Killing Cargo | Granzyme B, Granzyme A, perforin-associated proteins | Apoptosis induction |
Death-Receptor Cargo | FasL, TRAIL, TNF-family proteins | Extrinsic death signaling |
Immune Amplification Cargo | IFN-γ, TNF-α, IL-2-associated signals | Cytotoxic reinforcement |
Regulatory RNA | miR-155, miR-181, miR-29 | Killing program support |
Metabolic Cargo | Redox regulators, ATP-associated signals | Effector persistence |
SECTION III — CYTOTOXIC ADDRESSING SYSTEM
Address Layer | NK Logic | CTL Logic |
Recognition | Missing-self, stress ligands, viral ligands | Peptide-MHC-I recognition |
Docking | LFA-1, ICAM-1, CD2, CD58 | LFA-1, ICAM-1, TCR-MHC |
Authorization | NKG2D, NKp30, NKp44, NKp46 | TCR activation + costimulation |
Checkpoint Control | KIR, NKG2A, PD-1 | PD-1, LAG-3, TIM-3 |
SECTION IV — KILLING PROGRAMS
Program A — Tumor Surveillance
Cargo Signature:
- Granzyme B
- TRAIL
- IFN-γ
- miR-29
Outcome:
Tumor-cell apoptosis and immune amplification.
Program B — Viral Clearance
Cargo Signature:
- Granzyme B
- Perforin-associated proteins
- IFN-associated cargo
- Cytotoxic regulatory RNAs
Outcome:
Elimination of infected cells.
Program C — Senolytic Clearance
Cargo Signature:
- FasL
- TRAIL
- Stress-ligand targeting signals
Outcome:
Removal of senescent or dysfunctional cells.
Program D — Memory Surveillance
Cargo Signature:
- Persistent CTL-associated EV signals
- Recurrence-monitoring RNA cargo
- Antigen-specific cytotoxic markers
Outcome:
Long-term target suppression.
SECTION V — CYTOTOXIC FAULT ARCHITECTURE
Fault Node | EV Signaling Failure | Clinical Consequence |
Recognition Failure | Poor target identification | Tumor or viral escape |
Granzyme Deficiency | Weak apoptotic signaling | Reduced cytotoxicity |
Perforin Dysfunction | Failed delivery support | Incomplete killing |
Checkpoint Overload | PD-1/PD-L1-dominant inhibition | Exhaustion |
Cargo Degradation | Low-fidelity cytotoxic payload | Ineffective immune response |
Synapse Instability | Poor EV delivery | Failed target elimination |
SECTION VI — TUMOR COUNTERMEASURE MAP
Tumor Strategy | EV Mechanism | Result |
Checkpoint EV Release | PD-L1-rich EVs | CTL suppression |
Decoy EV Production | Nonproductive immune binding | Immune diversion |
Metabolic Suppression | Lactate/redox-altering cargo | Effector exhaustion |
Antigen Loss | Reduced MHC-I presentation | CTL escape |
Immunosuppressive Niche Formation | TGFβ/IL-10-rich EVs | Tolerance induction |
SECTION VII — HEMOREGEN BIOMARKER PANEL
NK EV Markers
- NKG2D
- NKp30
- NKp44
- NKp46
- CD56
CTL EV Markers
- CD8
- TCR-associated proteins
- IFN-γ cargo
Cytotoxic Cargo Markers
- Granzyme B
- Granzyme A
- FasL
- TRAIL
- Perforin-associated proteins
EV Identity Markers
- CD9
- CD63
- CD81
SECTION VIII — HEMOREGEN THERAPEUTIC ENGINEERING BLUEPRINT
HEM-RX-003A — Engineered NK-EV Therapeutics
Applications:
- Solid tumors
- Hematologic malignancies
- Viral reservoirs
HEM-RX-003B — Antigen-Specific CTL-EV Platform
Applications:
- Personalized oncology
- Neoantigen-directed therapy
HEM-RX-003C — Antiviral Cytotoxic EV Platform
Applications:
- Chronic viral infection
- Persistent infected-cell reservoirs
HEM-RX-003D — Senolytic EV Platform
Applications:
- Aging biology
- Regenerative medicine
- Chronic inflammatory degeneration
HEM-RX-003E — Multi-Target Cytotoxic EV Platform
Applications:
- Resistant cancers
- Tumor heterogeneity
- Immune escape prevention
SECTION IX — CYTOTOXIC EV PERFORMANCE INDEX
Domain | Score |
Target Recognition Accuracy | 0–20 |
Cytotoxic Cargo Potency | 0–20 |
Address Fidelity | 0–20 |
Checkpoint Resistance | 0–20 |
Target Elimination Persistence | 0–20 |
Total Score: 0–100
Score | Interpretation |
80–100 | High-fidelity cytotoxic EV network |
60–79 | Functional cytotoxic activity |
40–59 | Cytotoxic drift |
20–39 | Immune escape risk |
<20 | Cytotoxic communication collapse |
MASTER REGISTRY INDEX
HEMOREGEN-IMM-003 — NK/CTL Cytotoxic EV Blueprint
HEM-RX-003 — Cytotoxic EV Oncology Platform
HEM-RX-003A — Engineered NK-EV Therapeutics
HEM-RX-003B — Antigen-Specific CTL-EV Platform
HEM-RX-003C — Antiviral Cytotoxic EV Platform
HEM-RX-003D — Senolytic EV Platform
HEM-RX-003E — Multi-Target Cytotoxic EV Platform
HEMOREGEN-721-PROG-0001 — Project HEMOREGEN-721 Master Program
SCF-IMM-CYTO-0001 — Cytotoxic Immune Communication Systems Atlas
SCF-IMM-KILLNET-0001 — Cytotoxic Synapse Communication Network